<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>492</ReferenceId>
        <Keywords>An old reference of Michael sitting "for cross check review". It deals only with blacklisted epitope HBcAg18-27.</Keywords>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>15069731</PubmedId>
            <Abstract>AIM: To explore how to trigger an HLAI-restricted CD8(+) T cell response to exogenously synthesized polypeptides in vivo. METHODS: To explore how to trigger an HLAI-restricted CD8(+) T cell response to exogenously synthesized polypeptides in vivo.Three mimetic therapeutic polypeptides based on the immunodominant CTL epitope of HBcAg, the B- epitope of HBV PreS(2) region and a common T helper sequence of tetanus toxoid were designed and synthesized with Merrifield's solid-phase peptide synthesis method. Their immunological properties of inducing T( H1) polarization, CD8(+) HBV-specific CTL expansion and CD8(+) T cell mediated cytotoxicity were investigated in HLA-A2 transgenic mice. RESULTS: To explore how to trigger an HLAI-restricted CD8(+) T cell response to exogenously synthesized polypeptides in vivo.Three mimetic therapeutic polypeptides based on the immunodominant CTL epitope of HBcAg, the B- epitope of HBV PreS(2) region and a common T helper sequence of tetanus toxoid were designed and synthesized with Merrifield's solid-phase peptide synthesis method. Their immunological properties of inducing T( H1) polarization, CD8(+) HBV-specific CTL expansion and CD8(+) T cell mediated cytotoxicity were investigated in HLA-A2 transgenic mice.Results demonstrated that the mimetic polypeptides comprised of the immunodominant CTL, B-, and T helper epitopes could trigger specifically and effectively vigorous CD8(+) HBV-specific CTL-mediated cytotoxicity and T(H1) polarization of T cells in HLA-A2 transgenic mice. CONCLUSION: To explore how to trigger an HLAI-restricted CD8(+) T cell response to exogenously synthesized polypeptides in vivo.Three mimetic therapeutic polypeptides based on the immunodominant CTL epitope of HBcAg, the B- epitope of HBV PreS(2) region and a common T helper sequence of tetanus toxoid were designed and synthesized with Merrifield's solid-phase peptide synthesis method. Their immunological properties of inducing T( H1) polarization, CD8(+) HBV-specific CTL expansion and CD8(+) T cell mediated cytotoxicity were investigated in HLA-A2 transgenic mice.Results demonstrated that the mimetic polypeptides comprised of the immunodominant CTL, B-, and T helper epitopes could trigger specifically and effectively vigorous CD8(+) HBV-specific CTL-mediated cytotoxicity and T(H1) polarization of T cells in HLA-A2 transgenic mice.A designed universal T helper plus B-epitopes with short and flexible linkers could dramatically improve the immunogenicity of CTL epitopes in vivo. And that the mimetic therapeutic peptides based on the reasonable match of the above CTL, B- and T helper epitopes could be a promising therapeutic peptide vaccine candidate against HBV infection.</Abstract>
            <ArticleYear>2004</ArticleYear>
            <ArticlePages>1222-6</ArticlePages>
            <ArticleTitle>Therapeutic polypeptides based on HBcAg(18-27) CTL epitope can induce antigen-specific CD(8)(+) CTL-mediated cytotoxicity in HLA-A2 transgenic mice.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Shi</LastName>
                    <ForeName>Tong-Dong</ForeName>
                </Author>
                <Author>
                    <LastName>Wu</LastName>
                    <ForeName>Yu-Zhang</ForeName>
                </Author>
                <Author>
                    <LastName>Jia</LastName>
                    <ForeName>Zheng-Cai</ForeName>
                </Author>
                <Author>
                    <LastName>Zhou</LastName>
                    <ForeName>Wei</ForeName>
                </Author>
                <Author>
                    <LastName>Zou</LastName>
                    <ForeName>Li-Yun</ForeName>
                </Author>
            </Authors>
            <Affiliations>Institute of Immunology, Third Military Medical University, 30 Gaotanyan Street, Chongqing 400038, China. tdshih@yahoo.com.cn.</Affiliations>
            <ArticleChemicalList>HLA-A2 Antigen;Hepatitis B Core Antigens;Hepatitis B Vaccines;Immunodominant Epitopes</ArticleChemicalList>
            <ArticleMeshHeadingsList>Animals; CD8-Positive T-Lymphocytes(immunology); Female; HLA-A2 Antigen(genetics); Hepatitis B Core Antigens(immunology; pharmacology); Hepatitis B Vaccines(immunology); Hepatitis B, Chronic(immunology; prevention &amp; control); Immune Tolerance(immunology); Immunodominant Epitopes(immunology; pharmacology); Male; Mice; Mice, Transgenic</ArticleMeshHeadingsList>
            <Journal>
                <Volume>10</Volume>
                <Issue>8</Issue>
                <Title>World journal of gastroenterology : WJG</Title>
                <Issn>2219-2840</Issn>
                <MedlineTa>World J Gastroenterol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>HBcAg 18-27</EpitopeName>
                <EpitopeStructure>
                    <FragmentOfANaturalSequenceMolecule>
                        <ChemicalType>Peptide from protein</ChemicalType>
                        <LinearSequence>FLPSDFFPSV</LinearSequence>
                        <StartingPosition>18</StartingPosition>
                        <EndingPosition>27</EndingPosition>
                        <SourceMolecule>
                            <GenBankId>P03149.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>10407</SourceOrganismId>
                    </FragmentOfANaturalSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>Materials and Methods</LocationOfData>
                <EpitopeId>16833</EpitopeId>
                <ReferenceStartingPosition>18</ReferenceStartingPosition>
                <ReferenceEndingPosition>27</ReferenceEndingPosition>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 1</LocationOfData>
                        <TCellId>3273</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000582</OrganismId>
                                <Age>6-8 weeks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>FLPSDFFPSV</LinearSequence>
                                            <StartingPosition>18</StartingPosition>
                                            <EndingPosition>27</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P03149.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Peptide 3</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Peptide conjugate</ComplexType>
                                        <PeptideSequence>QYIKANSKFIGITEAAAFLPSDFFPSVGGGDPRVRGLYFPA</PeptideSequence>
                                        <PeptideModifications/>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>1 dose of 500 µg/kg and two weeks later, 4 doses of 250 µg/kg, administered weekly.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were injected with the epitope linked by three G residues to the tetanus toxin derived peptide QYIKANSKFIGITE and to the Pre-S2 B-epitope DPRVRGLYFPA (P3), and then with an irrelevant control peptide in CFA. Two weeks later mice were boosted four times with same antigens at IFA . Two weeks after last immunization, mice were killed, and spleen lymphocytes were used for assay. In two separate experiments, animals were immunized with the epitope alone (P1) or with the epitope conjugated to the tetanus toxin peptide (P2).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>Splenocyte</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                            <AutologousOrSyngeneic>Y</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>235</MhcAlleleId>
                            <MhcEvidenceCode>Cited reference</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>Peptide 1</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FLPSDFFPSV</LinearSequence>
                                        <StartingPosition>18</StartingPosition>
                                        <EndingPosition>27</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03149.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>48</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Figure 1</LocationOfData>
                        <TCellId>1855358</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000582</OrganismId>
                                <Age>6-8 weeks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>FLPSDFFPSV</LinearSequence>
                                            <StartingPosition>18</StartingPosition>
                                            <EndingPosition>27</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P03149.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Peptide 3</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Peptide conjugate</ComplexType>
                                        <PeptideSequence>QYIKANSKFIGITEAAAFLPSDFFPSVGGGDPRVRGLYFPA</PeptideSequence>
                                        <PeptideModifications/>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>1 dose of 500 µg/kg and two weeks later, 4 doses of 250 µg/kg, administered weekly.</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Mice were injected with the epitope linked by three G residues to the tetanus toxin derived peptide QYIKANSKFIGITE and to the Pre-S2 B-epitope DPRVRGLYFPA (P3), and then with an irrelevant control peptide in CFA. Two weeks later mice were boosted four times with same antigens at IFA . Two weeks after last immunization, mice were killed, and spleen lymphocytes were used for assay. In two separate experiments, animals were immunized with the epitope alone (P1) or with the epitope conjugated to the tetanus toxin peptide (P2).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Direct Ex Vivo</CellCultureConditions>
                        </EffectorCells>
                        <MhcAllele>
                            <MhcAlleleId>235</MhcAlleleId>
                            <MhcEvidenceCode>Cited reference</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>Peptide 1</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FLPSDFFPSV</LinearSequence>
                                        <StartingPosition>18</StartingPosition>
                                        <EndingPosition>27</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03149.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>47</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                        </AssayInformation>
                    </TCell>
                </Assays>
                <Assays>
                    <TCell>
                        <LocationOfData>Table 2</LocationOfData>
                        <TCellId>1855357</TCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000582</OrganismId>
                                <Age>6-8 weeks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>FLPSDFFPSV</LinearSequence>
                                            <StartingPosition>18</StartingPosition>
                                            <EndingPosition>27</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P03149.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>Peptide 3</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                                <ImmunogenContainingObject>
                                    <ComplexedMolecule>
                                        <ComplexType>Peptide conjugate</ComplexType>
                                        <PeptideSequence>QYIKANSKFIGITEAAAFLPSDFFPSVGGGDPRVRGLYFPA</PeptideSequence>
                                        <PeptideModifications/>
                                    </ComplexedMolecule>
                                </ImmunogenContainingObject>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Subcutaneous (s.c.)</Route>
                                <DoseSchedule>1 dose of 500 µg/kg and two weeks later, 4 doses of 250 µg/kg, administered weekly.</DoseSchedule>
                            </FirstInVivoProcess>
                            <InVitroAdministration>
                                <ProcessType>Restimulation in vitro</ProcessType>
                                <ResponderCellType>Splenocyte</ResponderCellType>
                                <StimulatorCellType>Splenocyte</StimulatorCellType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Epitope</EpitopeRelation>
                                    <Object>
                                        <FragmentOfANaturalSequenceMolecule>
                                            <ChemicalType>Peptide from protein</ChemicalType>
                                            <LinearSequence>FLPSDFFPSV</LinearSequence>
                                            <StartingPosition>18</StartingPosition>
                                            <EndingPosition>27</EndingPosition>
                                            <SourceMolecule>
                                                <GenBankId>P03149.1</GenBankId>
                                            </SourceMolecule>
                                            <SourceOrganismId>10407</SourceOrganismId>
                                        </FragmentOfANaturalSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenEvidenceCode>Exact match to reference information</ImmunogenEvidenceCode>
                            </InVitroAdministration>
                            <ImmunizationComments>Mice were injected with the epitope linked by three G residues to the tetanus toxin derived peptide QYIKANSKFIGITE and to the Pre-S2 B-epitope DPRVRGLYFPA (P3), and then with an irrelevant control peptide in CFA. Two weeks later mice were boosted four times with same antigens at IFA . Two weeks after last immunization, mice were killed, and spleen lymphocytes were used for assay. In two separate experiments, animals were immunized with the epitope alone (P1) or with the epitope conjugated to the tetanus toxin peptide (P2).</ImmunizationComments>
                        </Immunization>
                        <EffectorCells>
                            <CellTissueType>Spleen</CellTissueType>
                            <CellType>T cell CD8+</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                        </EffectorCells>
                        <AntigenPresentingCells>
                            <CellTissueType>Other</CellTissueType>
                            <CellType>P815-Mast cell</CellType>
                            <CellCultureConditions>Cell Line / Clone</CellCultureConditions>
                            <AutologousOrSyngeneic>N</AutologousOrSyngeneic>
                        </AntigenPresentingCells>
                        <MhcAllele>
                            <MhcAlleleId>235</MhcAlleleId>
                            <MhcEvidenceCode>Cited reference</MhcEvidenceCode>
                        </MhcAllele>
                        <Antigen>
                            <AntigenReferenceName>Peptide 1</AntigenReferenceName>
                            <AntigenObject>
                                <EpitopeRelation>Epitope</EpitopeRelation>
                                <Object>
                                    <FragmentOfANaturalSequenceMolecule>
                                        <ChemicalType>Peptide from protein</ChemicalType>
                                        <LinearSequence>FLPSDFFPSV</LinearSequence>
                                        <StartingPosition>18</StartingPosition>
                                        <EndingPosition>27</EndingPosition>
                                        <SourceMolecule>
                                            <GenBankId>P03149.1</GenBankId>
                                        </SourceMolecule>
                                        <SourceOrganismId>10407</SourceOrganismId>
                                    </FragmentOfANaturalSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Exact match to reference information</AntigenEvidenceCode>
                        </Antigen>
                        <AssayInformation>
                            <AssayTypeId>67</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                        </AssayInformation>
                    </TCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

